Table 3.

Comparison of clinical radiolabeled trastuzumab studies

Author	Agent	t1/2(h)	Tumor Type	n	HER2 Status	Trastuzumab pre-dose	Administered Dose	Lesion visibility	Organs receiving highest dose
Perik et al.[1]	111In-DTPA trastuzumab	67.9	Breast	17	All 3+	4mg/kg	100-150 MBq/5mg	At least 1 in 14/15 patients New lesions in 13/15	na
Gaykema et al. [2]1	111In-DTPA trastuzumab	67.9	Breast	12	+	4mg/kg + 2mg/kg weekly	100-150 MBq/5mg	25	liver, spleen, Myocardium
Wong et al [3]	111In-MxDTPA trastuzumab	67.9	Breast	8	≥3+	4-8 mg/kg	185 MBq/10mg	At least 1 in 3/7 patients	myocardium, liver, kidneys2
Dijkers et al[4]	89Zr-N-SucDf-trastuzumab	78.4	Breast	14	+	10[n=2], 50[n=5] OR 10mg[n=7] if on trastuzumab	38.4[1.6] MBq/1.5mg	All lesions in 6/12 patients	na
O’Donoghue et al[5]	89Zr-N-SucDf-trastuzumab	78.4	Gastroesophageal	10	3+(n=8) 2+FISH+(n=2)	50 mg	184(182 to 189) MBq /3mg	At least 1 in 8/10 patients	Liver, myocardium, kidneys
Tamur et al.[6]	64Cu-DOTA trastuzumab	12.7	Breast	6	3+(n=5) 2+FISH+(n=1)	86.2±6.3 μg	126±8MBq	At least 1 in 6/6 patients 9/11 lesions	myocardium, liver, spleen
Data from this manuscript	111In-CHX-A”-DTPA trastuzumab	67.9	Breast (n=8), NSCLC (n=2), Bladder (n=1)	11	3+(n=7) 2+FISH+(n=1) HER2(−)(n=3)	129.02[36.8] μg	175.7[20.3] MBq	10/11 Concordant with pathology	liver, bowel, myocardium

na = not available;

¹same patient population as above;

²dose calculations using ⁹⁰Y

Current publications of radiolabeled trastuzumab clinical imaging are limited by small numbers of patients and variable patient preparation and imaging protocols. Our is the only study that included HER2(−) patients and 1 of 2 in which additional non-radiolabeled trastuzumab was NOT given. Despite the numerous inconsistencies, HER2 imaging with radiolabeled trastuzumab is safe and feasible with PET or SPECT; however further validation studies with larger patient populations are needed